Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase NA 2Phase 3 1

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Other neoplasm 1Dermatologic 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Precancerous Conditions 1Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Basal Cell 1Basal Cell Nevus Syndrome 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Interventional × Comparative Genomic Hybridization × Clear all
NCT00433485 2016-09-23

Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants

Yale University

Phase 1 Completed
16 enrolled
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell, Neoplasms

NCT00389922 2012-04-19

Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors

University of California, Davis

Phase 1 Completed
22 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00569712 2012-03-09

Studying Genes in Blood and Lung Fluid Samples From Patients With Chronic Obstructive Pulmonary Disease With or Without a Previous Diagnosis of Lung Cancer or With Asthma Treated With Budesonide and Formoterol

British Columbia Cancer Agency

Phase 1 Completed
30 enrolled
Other neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡